Program
Trastuzumab
Also written as “Herceptin”, “trastuzumab [Herceptin]” and “trastuzumab”.
Its studies are mostly in Breast Neoplasms · Stomach Neoplasms · Colorectal Neoplasms · Neoplasms · Urologic Neoplasms, led by 20 companies.
Drug pageTrastuzumab: every studyMany companies study it; this page follows only the 78 they lead. All 533 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 470 open or running | phase 4since Dec 13, 2010 | May 2, 2000 | none ahead |
| Novartisits history only | 50 open or running | phase 4since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Pfizerits history only | 31 open or running | phase 3since Feb 14, 2022 | Oct 20, 2005 | Dec 31, 2027phase 3 · NCT05253651 |
| Celltrionits history only | 20 open or running | phase 3since Jun 11, 2014 | Jun 11, 2014 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 2since Aug 31, 2007 | Aug 31, 2007 | none ahead |
| Prestige Biopharmaits history only | 20 open or running | phase 3since Dec 29, 2016 | Dec 29, 2016 | none ahead |
| Sanofiits history only | 20 open or running | phase 3since Jul 11, 2001 | Jul 11, 2001 | none ahead |
| Sarah Cannon Research Instituteits history only | 21 open or running | phase 2since Jun 27, 2007 | Jun 27, 2007 | none ahead |
| Tanvex BioPharma USAits history only | 20 open or running | phase 3since Jun 1, 2018 | Jun 1, 2018 | none ahead |
| AryoGen Pharmedits history only | 10 open or running | phase 3since Nov 21, 2017 | Nov 21, 2017 | none ahead |
| Biocadits history only | 10 open or running | phase 3since Jan 7, 2013 | Jan 7, 2013 | none ahead |
| Cogent Biosciencesits history only | 10 open or running | phase 1since Sep 14, 2018 | Sep 14, 2018 | none ahead |
| Incepta Pharmaceuticalsits history only | 10 open or running | phase 1since Jan 12, 2025 | Jan 12, 2025 | none ahead |
| Jiangsu HengRui Medicineits history only | 11 open or running | phase 3since Aug 14, 2026 | Aug 14, 2026 | Feb 28, 2030phase 3 · NCT07779538 |
| Meiji Seika Pharmaits history only | 10 open or running | phase 1since Mar 27, 2014 | Mar 27, 2014 | none ahead |
| Merckits history only | 10 open or running | phase 2since May 27, 2008 | May 27, 2008 | none ahead |
| NovoCureits history only | 10 open or running | no phasesince Feb 20, 2020 | Feb 20, 2020 | none ahead |
| Orano Medits history only | 10 open or running | phase 1since Jun 27, 2011 | Jun 27, 2011 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 1since Mar 1, 2023 | Mar 1, 2023 | none ahead |
| Viatrisits history only | 10 open or running | phase 1since Oct 29, 2015 | Oct 29, 2015 | none ahead |
Also a collaborator on its studies: Daiichi Sankyo, Medivation LLC, a wholly owned subsidiary of Pfizer, AbbVie, Zai Lab, Nippon Kayaku, MDS Pharma Services, Mylan and Dong-A Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Dec 1, 2008.
- Apr 20, 2016Phase 2 study in Breast NeoplasmsHoffmann-La Roche · NCT02748213 · 225 enrolled · Australia, Brazil, Canada and more
- Jun 9, 2016Named trastuzumabINNProposed as its International Nonproprietary Name in WHO's List 115 · before, HD201
- Dec 29, 2016Prestige Biopharma’s first study: phase 3 study in Breast NeoplasmsNew to Prestige BiopharmaPrestige Biopharma · NCT03013504 · 503 enrolled · Belarus, Bulgaria, Estonia and more
- Nov 21, 2017AryoGen Pharmed’s first study: phase 3 study in Breast NeoplasmsNew to AryoGen PharmedAryoGen Pharmed · NCT03425656 · 108 enrolled · Iran, Islamic Republic of
- Dec 12, 2017Phase 2 study in Breast NeoplasmsSarah Cannon Research Institute · NCT03379428 · 34 enrolled · United States
- Jun 1, 2018Tanvex BioPharma USA’s first study: phase 3 study in Breast NeoplasmsNew to Tanvex BioPharma USATanvex BioPharma USA · NCT03556358 · 809 enrolled · Belarus, Chile, Georgia and more
- Sep 14, 2018Cogent Biosciences’ first study: phase 1 study in Breast NeoplasmsNew to Cogent BiosciencesCogent Biosciences · NCT03680560 · 6 enrolled · United States
- Dec 13, 2018Phase 1 study in Healthy VolunteersPrestige Biopharma · NCT03776240 · 105 enrolled · Australia
- Sep 20, 2019Phase 3 study in Breast NeoplasmsTanvex BioPharma USA · NCT04109391 · 338 enrolled · Belarus, Chile, Georgia and more
- Feb 20, 2020NovoCure’s first study: no phase study in Stomach NeoplasmsNew to NovoCureNovoCure · NCT04281576 · 28 enrolled · Hong Kong
- Feb 14, 2022Phase 3 study in Colorectal NeoplasmsPfizer · NCT05253651 · 325 enrolled · United States, Argentina, Australia and more
- Mar 1, 2023Sino Biopharmaceutical’s first study: phase 1 study in Breast NeoplasmsNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT05765357 · 89 enrolled · China
- Jan 12, 2025Incepta Pharmaceuticals’ first study: phase 1 study in Breast NeoplasmsNew to Incepta PharmaceuticalsIncepta Pharmaceuticals · NCT06886659 · 80 enrolled · Bangladesh
- Oct 6, 2025Phase 1 study in Healthy ParticipantsHoffmann-La Roche · NCT07214766 · 331 enrolled · United States
- Aug 14, 2026Jiangsu HengRui Medicine’s first study: phase 3 study in Ovarian NeoplasmsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT07779538 · 420 planned · China
Ahead
- Dec 31, 2027Primary completion: phase 3 study in Colorectal NeoplasmsPfizer · NCT05253651
- Feb 28, 2030Primary completion: phase 3 study in Ovarian NeoplasmsJiangsu HengRui Medicine · NCT07779538
TargetBeta
“A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2)”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
The newest 60 of 78 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07779538Ovarian Neoplasms · China | 3 | Recruiting | Jiangsu HengRui Medicine | Feb 28, 2030 | 420 |
| NCT07214766Healthy Participants · United States | 1 | Completed | Hoffmann-La Roche | Jul 3, 2026 | 331 |
| NCT06886659Breast Neoplasms · Bangladesh | 1 | Completed | Incepta Pharmaceuticals | Dec 28, 2024 | 80 |
| NCT05765357Breast Neoplasms · China | 1 | Completed | Sino Biopharmaceutical | Oct 27, 2017 | 89 |
| NCT05253651Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Dec 31, 2027 | 325 |
| NCT04281576Stomach Neoplasms · Hong Kong | – | Completed | NovoCure | Jun 7, 2024 | 28 |
| NCT04109391Breast Neoplasms · Belarus, Chile, Georgia and more | 3 | Completed | Tanvex BioPharma USA | Dec 25, 2021 | 338 |
| NCT03776240Healthy Volunteers · Australia | 1 | Completed | Prestige Biopharma | Aug 19, 2019 | 105 |
| NCT03680560Breast Neoplasms · United States | 1 | Terminated | Cogent Biosciences | Mar 12, 2020 | 6 |
| NCT03556358Breast Neoplasms · Belarus, Chile, Georgia and more | 3 | Completed | Tanvex BioPharma USA | Nov 27, 2020 | 809 |
| NCT03379428Breast Neoplasms · United States | 2 | Active, not recruiting | Sarah Cannon Research Institute | Jan 2025 | 34 |
| NCT03425656Breast Neoplasms · Iran, Islamic Republic of | 3 | Completed | AryoGen Pharmed | Mar 6, 2018 | 108 |
| NCT03013504Breast Neoplasms · Belarus, Bulgaria, Estonia and more | 3 | Completed | Prestige Biopharma | Apr 19, 2019 | 503 |
| NCT02748213Breast Neoplasms · Australia, Brazil, Canada and more | 2 | Completed | Hoffmann-La Roche | Mar 2006 | 225 |
| NCT02721641Neoplasms · Australia, Belgium, China and more | 3 | Completed | Hoffmann-La Roche | Feb 2015 | 69 |
| NCT02665637Healthy Volunteers · United States | 1 | Completed | Celltrion | Apr 2016 | 70 |
| NCT02594761Healthy | 1 | Completed | Viatris | Feb 2014 | 132 |
| NCT02536339Breast Neoplasms · United States | 2 | Completed | Hoffmann-La Roche | May 1, 2019 | 40 |
| NCT02419742Breast Neoplasms · India | 4 | Completed | Hoffmann-La Roche | Jun 24, 2021 | 110 |
| NCT02402712Breast Neoplasms · Belgium, Bulgaria, Canada and more | 3 | Completed | Hoffmann-La Roche | Feb 22, 2019 | 418 |
| NCT02291289Colorectal Neoplasms · Argentina, Belgium, Bosnia and Herzegovina and more | 2 | Completed | Hoffmann-La Roche | May 31, 2019 | 1,044 |
| NCT02213042Breast Neoplasms · United States, Argentina, Austria and more | 2 | Terminated | Novartis | Jun 4, 2020 | 42 |
| NCT02194166Breast Neoplasms · Belarus, Kazakhstan | 3 | Completed | Hoffmann-La Roche | Jul 12, 2018 | 90 |
| NCT02162667HER2-positive Carcinoma of Breast · Argentina, Belarus, Bosnia and Herzegovina and more | 3 | Completed | Celltrion | May 26, 2016 | 562 |
| NCT02132949Breast Neoplasms · United States, Canada, Denmark and more | 2 | Completed | Hoffmann-La Roche | Mar 3, 2016 | 401 |
| NCT02100917Neoplasms · Japan | 1 | Completed | Meiji Seika Pharma | May 2014 | 70 |
| NCT02091141Neoplasms · United States | 2 | Completed | Hoffmann-La Roche | May 24, 2023 | 673 |
| NCT02040935Breast Neoplasms · Netherlands | 3 | Completed | Hoffmann-La Roche | Sep 14, 2018 | 128 |
| NCT02019277Breast Neoplasms · Australia | 3 | Completed | Hoffmann-La Roche | Nov 4, 2016 | 50 |
| NCT02006667Urologic Neoplasms · Germany | 2 | Completed | Hoffmann-La Roche | Jan 2010 | 13 |
| NCT02005484Stomach Neoplasms · Austria, Germany | 2 | Terminated | Hoffmann-La Roche | Feb 2008 | 6 |
| NCT02015676Breast Neoplasms · Spain | 2 | Completed | Hoffmann-La Roche | Sep 2009 | 69 |
| NCT02013765Urologic Neoplasms · Germany | 2 | Terminated | Hoffmann-La Roche | Jan 2010 | 5 |
| NCT01998906Breast Neoplasms · Austria, Germany, Italy and more | 3 | Completed | Hoffmann-La Roche | Jul 2012 | 330 |
| NCT01964391Breast Neoplasms · Algeria, Morocco, Saudi Arabia and more | 3 | Completed | Hoffmann-La Roche | Dec 22, 2016 | 174 |
| NCT01940497Breast Neoplasms · Italy | 3 | Completed | Hoffmann-La Roche | Apr 5, 2016 | 240 |
| NCT01928615Breast Neoplasms · Austria | 2 | Terminated | Hoffmann-La Roche | Oct 2013 | 2 |
| NCT01926886Breast Neoplasms · Belgium, Israel | 3 | Completed | Hoffmann-La Roche | Sep 4, 2015 | 102 |
| NCT01810393Breast Neoplasms · France | 3 | Completed | Hoffmann-La Roche | Jul 17, 2019 | 114 |
| NCT01764022Breast Neoplasms · Belarus, India, Russian Federation and more | 3 | Completed | Biocad | Mar 2015 | 225 |
| NCT01748773Stomach Neoplasms · Turkey | 2 | Completed | Hoffmann-La Roche | Aug 21, 2015 | 34 |
| NCT01566721Breast Neoplasms · Albania, Algeria, Argentina and more | 3 | Completed | Hoffmann-La Roche | Mar 10, 2015 | 2,577 |
| NCT01450696Stomach Neoplasms · United States, Australia, Bosnia and Herzegovina and more | 3 | Terminated | Hoffmann-La Roche | Feb 2015 | 296 |
| NCT01401166Breast Neoplasms · Canada, Denmark, France and more | 2 | Completed | Hoffmann-La Roche | May 2013 | 488 |
| NCT01384253Breast Neoplasms · United States | 1 | Completed | Orano Med | Oct 2015 | 18 |
| NCT01363986Breast Neoplasms · Italy | 2 | Terminated | Hoffmann-La Roche | Jun 2012 | 3 |
| NCT01344863Healthy Volunteer · New Zealand | 1 | Completed | Hoffmann-La Roche | Jan 2012 | 119 |
| NCT01301729Breast Neoplasms · China | 4 | Completed | Hoffmann-La Roche | Jul 2014 | 32 |
| NCT01290718Breast Neoplasms · Taiwan | 2 | Terminated | Hoffmann-La Roche | Dec 2012 | 4 |
| NCT01260194Stomach Neoplasms · India | 4 | Terminated | Hoffmann-La Roche | Jan 2015 | 4 |
| NCT01160211Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Novartis | Mar 11, 2016 | 369 |
| NCT01137994Breast Neoplasms | 2 | Withdrawn | GlaxoSmithKline | Dec 2016 | 0 |
| NCT01130337Stomach Neoplasms · Spain | 2 | Completed | Hoffmann-La Roche | Jun 2014 | 36 |
| NCT01041404Stomach Neoplasms · Australia, Belgium, Brazil and more | 3 | Completed | Hoffmann-La Roche | Jun 2010 | 584 |
| NCT00964704Breast Neoplasms | 2 | Withdrawn | Hoffmann-La Roche | Aug 2013 | 0 |
| NCT00950300Breast Neoplasms · Argentina, Brazil, Canada and more | 3 | Completed | Hoffmann-La Roche | Jul 12, 2011 | 596 |
| NCT00927589Solid Cancers · United States | 1 | Completed | Hoffmann-La Roche | Feb 2013 | 59 |
| NCT00885755Breast Neoplasms · Australia, Spain, Sweden and more | 2 | Completed | Hoffmann-La Roche | Feb 18, 2013 | 33 |
| NCT00811135Breast Neoplasms · Denmark, France, Russian Federation and more | 2 | Completed | Hoffmann-La Roche | Dec 2015 | 88 |
| NCT00800436Breast Neoplasms · Australia, New Zealand | 1 | Completed | Hoffmann-La Roche | Oct 2009 | 66 |
How it is read
Names in the registry
- “Trastuzumab”, 36 entries
- “Herceptin”, 13 entries
- “trastuzumab [Herceptin]”, 11 entries
- “trastuzumab”, 9 entries
- “HD201”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 62 studies
- Stomach Neoplasms, 7 studies
- Colorectal Neoplasms, 2 studies
- Neoplasms, 2 studies
- Urologic Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.